Novo Nordisk A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novo Nordisk A/S
Novartis has failed to reach a reimbursement agreement to keep its first-in-class advanced breast cancer drug on the German market, but it is pressing on with plans to expand market access for the product across Europe. It is also working on securing regulatory approval to use Piqray in a broader patient population that would carve out a more meaningful place in the relevant treatment pathway.
Novo Nordisk at its Q1 update lifted full-year guidance and voiced confidence it can double sales of innovative treatments for obesity by 2025.
A number of advanced therapies are likely to be approved in the EU this year.
Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.
- Large Molecule
- Other Names / Subsidiaries
- Corvidia Therapeutics
- Neose Technologies, Inc.
- Novo Holdings A/S
- Novo Nordisk Pharmaceuticals, Inc.
- Pharmaero Aps
- Xellia Pharmaceuticals ApS
- Ziylo Ltd